TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05473468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
Study: NCT04555798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem Injection
Description: patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A-V ECMO
Description: Only patients of group B connected to A-V ECMO for two weeks
Study: NCT05129527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InspirerMundi app
Description: Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
Study: NCT05595460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level 1
Description: Dose Level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level 2
Description: Dose Level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level 3
Description: Dose Level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level -1
Description: Dose Level -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide
Study: NCT06111963

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology tests
Description: CD4, CD25, IL17

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology tests
Description: CD4, CD25, IL17
Study: NCT05308979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
Study: NCT05098639

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BASICS
Description: In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS
Description: In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deviance Regulation Theory (DRT)
Description: The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deviance Regulation Theory (DRT)
Description: The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
Study: NCT05824078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgery
Description: Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Description: The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
Study: NCT05333133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high calorie formula (oral nutritional supplement/ONS)
Description: every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90.
Study: NCT05118841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Study: NCT06277245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001
Description: Capsule; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001
Description: Capsule; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001
Description: Capsule; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule; Oral
Study: NCT05118841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Study: NCT06277245

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule; Oral
Study: NCT05118841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Study: NCT05208021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (Motivational Interviewing)
Description: The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
Study: NCT04927065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.211
Description: Sterile liquid for injection
Study: NCT06029803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adrenal Venous Sampling via Antecubital Approach
Description: Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adrenal Venous Sampling via Femoral Approach
Description: Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
Study: NCT04927065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.211
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.617.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.617.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.213
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.213
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.213
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Sterile liquid for injection
Study: NCT05024266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
Study: NCT04927065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.815
Description: Sterile liquid for injection
Study: NCT04864353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RestDep: Internet-delivered intervention targeting residual cognitive symptoms
Description: The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
Study: NCT04927065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.231
Description: Sterile liquid for injection
Study: NCT05206916

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryotherapy
Description: Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
Study: NCT05795309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Automated Insulin Delivery
Description: Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
Study: NCT06450405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Cypionate 50 MG/ML Injectable Solution
Description: Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
Study: NCT05524935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Day 1 of each 21 day (3 week) cycle
Study: NCT04980599

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic drink with Lactobacillus paracasei K56
Description: Probiotic drink (K56 10\^11CFU) 350ml/d for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin ,for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic powder E3
Description: Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic powder E5
Description: probiotic powder 8g/day for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E7
Description: probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E9
Description: probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E10
Description: probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E11
Description: probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
Study: NCT06566742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO
Study: NCT06300060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Daily administration in a single dose in powder form.
Study: NCT06576934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.
Study: NCT06651034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
Study: NCT05524935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
Study: NCT06647121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Psychoeducational Workshop
Description: The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT Psychoeducational Workshop
Description: The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTaide Mobile App
Description: The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders-only mobile app
Description: This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
Study: NCT06035601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EHR-integrated texting platform (Urotrust)
Description: * An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~* Evidence-based prevention education material on recurrent UTIs~* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment~* Standard-of-care management for recurrent UTI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: • Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
Study: NCT06377059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WARD
Description: Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
Study: NCT05913609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yaari Extractor
Description: The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.
Study: NCT05725928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility technician
Description: Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
Study: NCT06686888

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA
Description: On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA
Description: On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcristalline cellulose
Description: On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
Study: NCT06634199

Intervention type: DRUG
Intervention: Durvalumab
Description: Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
Study: NCT06705842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: After removal of the appendix from the patient's abdomen and attainment of hemostasis, 10 mL/kg of 1% PVI (up to a maximum of 1,000 mL) will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned out

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Surgeons may utilize local irrigation with saline if deemed necessary, defined as instillation of a small volume (\<100 mL) of liquid followed by aspiration, for the purpose of confirming hemostasis or suctioning thick fluid. Some surgeons may utilize large volume irrigation with saline solution, if that is consistent with their usual practice. Patients in the usual care arm will not receive PVI irrigation.
Study: NCT06721702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviews were administered as the intervention of the research. Motivational interviewing consists of two stages. In the first stage, the four principles of motivational interviewing (developing contradiction, showing empathy, supporting self-efficacy, and resolving resistance) are aimed at providing motivation in individuals. The second stage is strengthening the commitment to change.